Evofem Biosciences (EVFM)
OTHER OTC:EVFM
Want to see EVFM full AI Analyst Report?
EVFM Stock Chart & Stats
$0.01
>-$0.01(-8.76%)
At close: 4:00 PM EST
$0.01
>-$0.01(-8.76%)
Day’s Range― - ―
52-Week Range<$0.01 - $0.02
Previous CloseN/A
Volume1.62M
Average Volume (3M)589.38K
Market Cap
$914.46K
Enterprise Value$66.22M
Total Cash (Recent Filing)$578.00K
Total Debt (Recent Filing)$65.87M
Price to Earnings (P/E)3.0
Beta-0.01
Next Earnings
Aug 11, 2026EPS EstimateN/A
Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)>-0.01
Shares Outstanding132,530,080
10 Day Avg. Volume412,838
30 Day Avg. Volume589,380
Financial Highlights & Ratios
PEG Ratio-0.03
Price to Book (P/B)-0.02
Price to Sales (P/S)0.06
P/FCF Ratio-0.59
Enterprise Value/Market Cap72.41
Enterprise Value/Revenue3.28
Enterprise Value/Gross Profit4.39
Enterprise Value/Ebitda32.07
Forecast
1Y Price TargetN/A
Price Target UpsideN/A
Rating ConsensusN/A
Number of Analyst Covering0
EPS Forecast (FY)57.5
Revenue Forecast (FY)$241.13M
Bulls Say, Bears Say
Bulls Say
Geographic Expansion Via Solosec DistributionA five-year exclusive distribution pact opens a durable, large addressable market in sub‑Saharan Africa and leverages Evofem’s FDA dossier for faster local filings. Partnering shifts commercialization execution to a local specialist, reducing capex and enabling revenue diversification outside the U.S.
Operational Cost Reductions And Profitability InitiativeMaterial expense cuts and reported operating income signal improved cost structure discipline. Combined with ongoing manufacturing cost reduction programs and regulatory progress in new markets, these initiatives can sustainably improve margins and reduce cash burn if maintained beyond one-time gains.
Niche Product Portfolio In Women's HealthA focused franchise in non‑hormonal sexual and reproductive health addresses a persistent, defensible clinical need. FDA approvals and differentiated, single‑dose therapies support durable demand, easier go‑to‑market clarity, and potential pricing leverage versus commodity multi‑dose treatments.
Bears Say
Highly Stressed Balance SheetDeeply negative equity and a debt load far exceeding assets materially constrain financial flexibility. This capital structure elevates refinancing and going‑concern risk, limits ability to fund growth or commercial rollouts internally, and increases reliance on external financing or partner deals.
Persistent Negative Cash FlowConsistent operating and free cash flow deficits mean the company must continuously access external capital or monetize assets. Even with burn improvement versus earlier years, recurring negative cash flow undermines self‑funding capacity and raises dilution and liquidity risks over the medium term.
Severe Revenue Disruption And InconsistencyA collapse to zero reported revenue indicates a fundamental commercial disruption or reporting anomaly that destroys earnings quality. Such volatility undermines forecasting, suggests fragile customer or supply dynamics, and casts doubt on the sustainability of any recent margin improvements.
Evofem Biosciences News
EVFM FAQ
What was Evofem Biosciences’s price range in the past 12 months?
Evofem Biosciences lowest stock price was <$0.01 and its highest was $0.02 in the past 12 months.
What is Evofem Biosciences’s market cap?
Evofem Biosciences’s market cap is $914.46K.
When is Evofem Biosciences’s upcoming earnings report date?
Evofem Biosciences’s upcoming earnings report date is Aug 11, 2026 which is in 98 days.
How were Evofem Biosciences’s earnings last quarter?
Currently, no data Available
Is Evofem Biosciences overvalued?
According to Wall Street analysts Evofem Biosciences’s price is currently Overvalued.
Does Evofem Biosciences pay dividends?
Evofem Biosciences does not currently pay dividends.
What is Evofem Biosciences’s EPS estimate?
Evofem Biosciences’s EPS estimate for its next earnings report is not yet available.
How many shares outstanding does Evofem Biosciences have?
Evofem Biosciences has 132,530,080 shares outstanding.
What happened to Evofem Biosciences’s price movement after its last earnings report?
Currently, no data Available
Which hedge fund is a major shareholder of Evofem Biosciences?
Currently, no hedge funds are holding shares in EVFM
What is the TipRanks Smart Score and how is it calculated?
Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology
Company Description
Evofem Biosciences
Evofem Biosciences, Inc., a biopharmaceutical company, develops and commercializes various products to address unmet needs in women's sexual and reproductive health. Its commercial product is Phexxi, a vaginal gel for the prevention of pregnancy. The company is also involved in the development of EVO100, an antimicrobial vaginal gel for the prevention of urogenital transmission of Chlamydia trachomatis infection and Neisseria gonorrhoeae infection in women. Evofem Biosciences, Inc. is headquartered in San Diego, California.
Technical Analysis
Ownership Overview
―
Insiders
―
Mutual Funds
<0.01% Other Institutional Investors
100.00% Public Companies and
Individual Investors
Options Prices
Currently, No data available
---